Neoadjuvant immune checkpoint inhibitors in cancer, current state of the art.
Cancer
Immunotherapy
Neoadjuvant
Preclinical data
Journal
Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
22
03
2020
revised:
22
10
2020
accepted:
05
11
2020
pubmed:
6
12
2020
medline:
23
1
2021
entrez:
5
12
2020
Statut:
ppublish
Résumé
Immunotherapy has been a revolution in cancer management in the metastatic setting. This has led to a prompt evaluation of such therapies in earlier stages. This article discusses the still limited amount of data finding the rationale to assess such therapy in this setting and reviews preclinical and clinical data available. Overall, neoadjuvant immunotherapy is a promising approach for the treatment of cancers and the rationale supporting its use is strong. Neoadjuvant immunotherapy resulted, in the majority of clinical trials, in improved pathologic complete response rates with a favorable toxicity profile and no delay in surgery. Various regimens were effective: inhibitory immune check-point blockers (IICPB) alone, combination of PD-1 and CTLA-4 inhibitors, combination of chemotherapy (CT) and IICPB, phased CT and IICPB (either IICPB before CT or IICPB after CT). Yet the question whether neoadjuvant immunotherapy will benefit to patients in terms of disease-free and, ultimately, overall survival remains unknown.
Identifiants
pubmed: 33278676
pii: S1040-8428(20)30308-5
doi: 10.1016/j.critrevonc.2020.103172
pii:
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Immunologic Factors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
103172Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.